Mast-Cell Stabilizing Effects of Olopatadine
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Conjunctivitis
Intervention: Olopatadine (generic name) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Alcon Research Official(s) and/or principal investigator(s): Terry Wiernas, Study Director, Affiliation: Alcon Research
Summary
To assess the effects of olopatadine of the release of mast cell histamine
Clinical Details
Official title: Mast-Cell Stabilizing Effects of Olopatadine
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Primary outcome: Tear histamine
Secondary outcome: Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asymptomatic and not using any topical or systemic medication
Exclusion Criteria:
- Age
Locations and Contacts
Padova Site, Padova, Italy
Additional Information
Starting date: October 2006
Last updated: January 4, 2010
|